11,671 Shares in Harrow, Inc. (NASDAQ:HROW) Bought by Graham Capital Management L.P.

Graham Capital Management L.P. acquired a new position in shares of Harrow, Inc. (NASDAQ:HROW - Free Report) in the fourth quarter, according to its most recent disclosure with the SEC. The firm acquired 11,671 shares of the company's stock, valued at approximately $392,000.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Tower Research Capital LLC TRC raised its holdings in Harrow by 769.5% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,652 shares of the company's stock worth $55,000 after purchasing an additional 1,462 shares in the last quarter. Aquatic Capital Management LLC acquired a new position in Harrow during the 4th quarter worth approximately $78,000. AlphaQuest LLC raised its stake in shares of Harrow by 452.8% during the 4th quarter. AlphaQuest LLC now owns 3,527 shares of the company's stock worth $118,000 after buying an additional 2,889 shares in the last quarter. Federated Hermes Inc. acquired a new stake in shares of Harrow in the 4th quarter valued at approximately $214,000. Finally, Maridea Wealth Management LLC purchased a new stake in shares of Harrow in the fourth quarter valued at approximately $222,000. 72.76% of the stock is currently owned by hedge funds and other institutional investors.

Harrow Price Performance

Shares of HROW stock traded down $1.04 during midday trading on Thursday, reaching $25.70. 56,184 shares of the company traded hands, compared to its average volume of 495,414. The firm's 50 day simple moving average is $25.33 and its two-hundred day simple moving average is $31.63. The firm has a market cap of $942.62 million, a PE ratio of -27.31 and a beta of 0.41. The company has a debt-to-equity ratio of 3.23, a current ratio of 1.55 and a quick ratio of 1.44. Harrow, Inc. has a 1-year low of $15.97 and a 1-year high of $59.23.

Harrow (NASDAQ:HROW - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by ($0.40). The firm had revenue of $47.83 million for the quarter, compared to analyst estimates of $57.00 million. Harrow had a negative return on equity of 45.57% and a negative net margin of 19.75%. On average, equities research analysts expect that Harrow, Inc. will post -0.53 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the company. B. Riley dropped their price objective on Harrow from $69.00 to $65.00 and set a "buy" rating on the stock in a report on Tuesday, April 1st. HC Wainwright upped their price target on shares of Harrow from $57.00 to $60.00 and gave the stock a "buy" rating in a research note on Monday, May 12th.

Harrow Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.